The goal of the GENERATE Study is to improve genetic testing and cancer prevention in family members of pancreatic cancer patients who may have genetic mutations (inherited changes). The study will measure how different methods of genetic education increase the rate of genetic testing in these families. This is an investigational study to measure the effects of two methods of genetic education. Participants may elect to undergo genetic testing as part of the study and will be asked to provide a saliva sample via a saliva-testing kit. The genetic testing done in this study is FDA approved and will be processed in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. Up to 1,000 participants will be enrolled in this study.

NCT03762590

Conditions

1. Candidates for Hereditary Pancreatic Cancer Testing

Interventions

1. Other: Doxy.me genetic education +/- Color Genomics genetic education
2. Other: Color Genomics genetic education

MeSH:Pancreatic Neoplasms

HPO:Neoplasm of the pancreas

leukemia or lymphoma) - Individual who is unable to sign the informed consent because of mental incompetency or psychiatric illness - Individual who is unwilling to complete baseline and follow-up questionnaires - Individual who has a life expectancy of less than 1 year - Individual with only APC I1307K mutation within their family - Individual with only PMS2 exons 12-15 deletion mutation within their family Inclusion Criteria: - Individual who is 18 years or older - Individual who has signed the informed consent - Individual with: --A first-degree relative who has (or had) pancreatic ductal adenocarcinoma (PDAC) OR a second-degree relative who has (or had) PDAC and has a known germline mutation in APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, or TP53 - The germline mutation and history of PDAC must be on the maternal side or paternal side of the individual's family - Individual with a valid United States mailing address - Individual with access to a healthcare provider and is willing to share genetic test results with that provider/the study team Exclusion Criteria: - Individual with a known cancer susceptibility gene - Individual who has received genetic counseling for cancer risk within the last 3 years - Individual who has received a bone marrow transplant, who has had a blood transfusion within the last 7 days, or who has an active hematologic malignancy (i.e. --- I1307K ---

leukemia or lymphoma) - Individual who is unable to sign the informed consent because of mental incompetency or psychiatric illness - Individual who is unwilling to complete baseline and follow-up questionnaires - Individual who has a life expectancy of less than 1 year - Individual with only APC I1307K mutation within their family - Individual with only PMS2 exons 12-15 deletion mutation within their family Candidates for Hereditary Pancreatic Cancer Testing Pancreatic Neoplasms Around 1 in 10 (10%) pancreatic cancer patients carries an inherited change (mutation) in a gene which can increase the risk of cancer. --- I1307K ---

The aim of this study is to determine the frequency of the three most common BRCA1 and BRCA2 genetic mutations that are commonly found in Ashkenazi Jewish patients with pancreatic cancer. Testing for BRCA1 and BRCA2 mutations in relatives of hereditary pancreatic cancer patients may have a significant impact; allowing for early screening, treatment, and resection of pre-malignant tissue or malignant lesions.

NCT01102569

Conditions

1. Pancreatic Cancer

MeSH:Pancreatic Neoplasms

HPO:Neoplasm of the pancreas

Determine the frequency of disease modifying mutations such as MSH2 A636P, APC I1307K, P53, R72P, CHEK2 S428F, RAD51 G135C and MTHFR V222A.. Inclusion Criteria: - Patients diagnosed with pancreatic cancer. --- A636P --- --- I1307K ---